Профиль циркулирующих микроРНК у пациентов с псориатическим артритом

Псориатический артрит (ПсА) является распространенным ревматическим заболеванием с чрезвычайно вариабельным фенотипом. Основными доменами ПсА являются периферический артрит, спондилит, энтезит и дактилит. Изучение новых механизмов развития ПсА может помочь в поиске ключа к разработке инновационных методов диагностики и персонализированных подходов к лечению этого заболевания. В последние годы активно изучается роль некодирующих рибонуклеиновых кислот (РНК), при этом наибольший интерес исследователей и клиницистов сконцентрирован на изучении роли микроРНК.

Цель настоящего обзора состоит в поиске, обобщении и систематизации доклинических и клинических исследований роли циркулирующих микроРНК в развитии ПсА и обновлении знаний о молекулярных биомаркерах этого заболевания. Авторами проведен поиск публикаций в наукоемких базах данных PubMed, Springer, Web of Science, Clinicalkeys, Scopus, OxfordPress, Cochrane, e-Libray с использованием ключевых слов и их комбинаций. Были проанализированы публикации за 2013-2023 гг., включая оригинальные клинические исследования ПсА и псориаза (ПсО). В результате этого описательного обзора показано, что miR-10b-5p, miR-126-3p, miR-151a-5p и miR-130a-3p могут рассматриваться как перспективные молекулярные биомаркеры ПсА и терапевтического ответа. Однако роль других микроРНК требует обсуждения и нуждается в дальнейшем изучении. В будущем можно будет рассматривать ранее изученные циркулирующие микроРНК, обладающие высокой специфичностью и чувствительностью при ПсА в качестве прогностических молекулярных биомаркеров (предикторов) риска развития и тяжести этого заболевания у пациентов с ПсО.

1. Dozmorov M.G., Giles C.B., Koelsch K.A., Wren J.D. Systematic classification of non-coding RNAs by epigenomic similarity. BMC Bioinformatics. 2013;14 Suppl 14(Suppl 14):S2. https://doi.org/10.1186/1471-2105-14-S14-S2

2. Ratti M., Lampis A., Ghidini M., Salati M., Mirchev M.B., Valeri N., Hahne J.C. MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside. Target. Oncol. 2020;15(3):261-278. https://doi.org/10.1007/s11523-020-00717-x

3. Fukao A., Aoyama T., Fujiwara T. The molecular mechanism of translational control via the communication between the microRNA pathway and RNA-binding proteins. RNA Biol. 2015;12(9):922-926. https://doi.org/10.1080/15476286.2015.1073436

4. Kozomara A., Birgaoanu M., Griffiths-Jones S. miRBase: from microRNA sequences to function. Nucleic Acids Res. 2019;47(D1):D155-D162. https://doi.org/10.1093/nar/gky1141

5. Singh R.P., Massachi I., Manickavel S., Singh S., Rao N.P., Hasan S., Mc Curdy D.K., Sharma S., Wong D., Hahn B.H., Rehimi H. The role of miRNA in inflammation and autoimmunity. Autoimmun Rev. 2013;12(12):1160-1165. https://doi.org/10.1016/j.autrev.2013.07.003

6. O’Connell R.M., Rao D.S., Chaudhuri A.A., Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat. Rev. Immunol. 2010;10(2):111-122. https://doi.org/10.1038/nri2708

7. Li Z.C., Han N., Li X., Li G., Liu Y.Z., Sun G.X., Wang Y., Chen G.T., Li G.F. Decreased expression of microrna-130a correlates with TNF-alpha in the development of osteoarthritis. Int. J. Clin. Exp. Pathol. 2015;8(3):2555-2564.

8. Nakasa T., Nagata Y., Yamasaki K., Ochi M. A mini-review: microRNA in arthritis. Physiol. Genomics. 2011;43(10):566-570. https://doi.org/10.1152/physiolgenomics.00142.2010

9. Pivarcsi A., Ståhle M., Sonkoly E. Genetic polymorphisms altering microRNA activity in psoriasis--a key to solve the puzzle of missing heritability? Exp. Dermatol. 2014;23(9):620-624. https://doi.org/10.1111/exd.12469

10. Løvendorf M.B., Mitsui H., Zibert J.R., Røpke M.A., Hafner M., Dyring-Andersen B., Bonefeld C.M., Krueger J.G., Skov L. Laser capture microdissection followed by next-generation sequencing identifies disease-related microRNAs in psoriatic skin that reflect systemic microRNA changes in psoriasis. Exp. Dermatol. 2015;24(3):187-193. https://doi.org/10.1111/exd.12604

11. Xiao S., Liu X., Wang X., Lv H., Zhao J., Guo X., Xian F., Ji Y., Zhang G. Plasma MicroRNA Expression Profiles in Psoriasis. J. Immunol. Res. 2020;2020:1561278. https://doi.org/10.1155/2020/1561278

12. Haschka J., Simon D., Bayat S., Messner Z., Kampylafka E., Fagni F., Skalicky S., Hackl M., Resch H., Zwerina J., Kleyer A., Cavallaro A., Sticherling M., Schett G., Kocijan R., Rech J. Identification of circulating microRNA patterns in patients in psoriasis and psoriatic arthritis. Rheumatology (Oxford). 2023;62(10):3448-3458. https://doi.org/10.1093/rheumatology/kead059

13. Villani A.P., Rouzaud M., Sevrain M., Barnetche T., Paul C., Richard M.A., Beylot-Barry M., Misery L., Joly P., Le Maitre M., Aractingi S., Aubin F., Cantagrel A., Ortonne J.P., Jullien D. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. J. Am. Acad. Dermatol. 2015;73:242-248. https://doi.org/10.1016/j.jaad.2015.05.001

14. Коротаева Т.В., Корсакова Ю.Л., Логинова Е.Ю., Губарь Е.Е., Чамурлиева М.Н. Псориатический артрит. Клинические рекомендации по диагностике и лечению. Современная ревматология. 2018;12(2):22-35. https://doi.org/10.14412/1996-7012-2018-2-22-35

15. Ocampo D.V., Gladman D. Psoriatic arthritis. F1000Res. 2019;8:(F1000 Faculty Rev.):1665. https://doi.org/10.12688/f1000research.19144.1

16. Coates L.C., Helliwell P.S. Psoriatic arthritis: state of the art review. Clin. Med. (Lond). 2017;17(1):65-70. https://doi.org/10.7861/clinmedicine.17-1-65

17. Olivieri I., Padula A., D’Angelo S., Cutro M.S. Psoriatic arthritis sine psoriasis. J. Rheumatol. Suppl. 2009;83:28-29. https://doi.org/10.3899/jrheum.090218

18. Pasquali L., Svedbom A., Srivastava A., Rosén E., Lindqvist U., Ståhle M., Pivarcsi A., Sonkoly E. Circulating microRNAs in extracellular vesicles as potential biomarkers for psoriatic arthritis in patients with psoriasis. J. Eur. Acad. Dermatol. Venereol. 2019;34(6):1248-1256. https://doi.org/10.1111/jdv.16203

19. Haroon M., Gallagher P., FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann. Rheum. Dis. 2015;74:1045-1050. https://doi.org/10.1136/annrheumdis-2013-204858

20. Lättekivi F., Guljavina I., Midekessa G., Viil J., Heath P.R., Bæk R., Jørgensen M.M., Andronowska A., Kingo K., Fazeli A. Profiling Blood Serum Extracellular Vesicles in Plaque Psoriasis and Psoriatic Arthritis Patients Reveals Potential Disease Biomarkers. Int. J. Mol. Sci. 2022;23(7):4005. https://doi.org/10.3390/ijms23074005

21. Mc Ardle A., Flatley B., Pennington S.R., FitzGerald O. Early biomarkers of joint damage in rheumatoid and psoriatic arthritis. Arthritis Res Ther. 2015;17(1):141. https://doi.org/10.1186/s13075-015-0652-z

22. Generali E., Scirè C.A., Favalli E.G., Selmi C. Biomarkers in psoriatic arthritis: A systematic literature review. Expert Rev. Clin. Immunol. 2016;12:651-660. https://doi.org/10.1586/1744666X.2016.1147954

23. Arican O., Aral M., Sasmaz S., Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005;2005(5):273-279. https://doi.org/10.1155/MI.2005.273

24. Kagami S., Rizzo H.L., Lee J.J., Koguchi Y., Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J. Invest. Dermatol. 2010;130(5):1373-1383. https://doi.org/10.1038/jid.2009.399

25. Eder L., Jayakar J., Pollock R., Pellett F., Thavaneswaran A., Chandran V., Rosen C.F., Gladman D.D. Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann. Rheum. Dis. 2013;72(12):1956-1961. https://doi.org/10.1136/annrheumdis-2012-202325

26. Chandran V., Cook R.J., Edwin J., Shen H., Pellett F.J., Shanmugarajah S., Rosen C.F., Gladman D.D. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford). 2010;49(7):1399-1405. https://doi.org/10.1093/rheumatology/keq105

27. Sokolova MV, Simon D, Nas K, Zaiss MM, Luo Y, Zhao Y, Rech J, Schett G. A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations. Arthritis Res. Ther. 2020;22(1):26. https://doi.org/10.1186/s13075-020-2111-8

28. Tamagawa-Mineoka R., Katoh N., Kishimoto S. Platelet activation in patients with psoriasis: Increased plasma levels of plateletderived microparticles and soluble P-selectin. J. Am. Acad. Dermatol. 2010;62:621-626. https://doi.org/10.1016/j.jaad.2009.06.053

29. Bos F., Capsoni F., Molteni S., Raeli L., Diani M., Altomare A., Garavaglia M., Garutti C., Frigerio E., Banfi G., Altomare G., Reali E. Differential expression of interleukin-2 by anti-CD3-stimulated peripheral blood mononuclear cells in patients with psoriatic arthritis and patients with cutaneous psoriasis. Clin. Exp. Dermatol. 2014;39:385- 390. https://doi.org/10.1111/ced.12251

30. Wade S.M., McGarry T., Wade S.C., Fearon U., Veale D.J. Serum MicroRNA Signature as a Diagnostic and Therapeutic Marker in Patients with Psoriatic Arthritis. J. Rheumatol. 2020;47(12):1760-1767. https://doi.org/10.3899/jrheum.190602

31. Wade S.M., McGarry T., Wade S.C., Fearon U., Veale D.J. Serum MicroRNA Signature as a Diagnostic and Therapeutic Marker in Patients with Psoriatic Arthritis. J. Rheumatol. 2020;47(12):1760-1767. https://doi.org/10.3899/jrheum.190602

32. Paek SY, Han L, Weiland M, Lu CJ, McKinnon K, Zhou L, Lim HW, Elder JT, Mi QS. Emerging biomarkers in psoriatic arthritis. IUBMB Life. 2015;67(12):923-927. https://doi.org/10.1002/iub.1453

33. Alberro A., Iparraguirre L., Fernandes A., Otaegui D. Extracellular vesicles in blood: Sources, effects, and applications. Int. J. Mol. Sci. 2021;22:8163. https://doi.org/10.3390/ijms22158163

34. Palviainen M., Saraswat M., Varga Z., Kitka D., Neuvonen M., Puhka M., Joenväärä S., Renkonen R., Nieuwland R., Takatalo M., Siljander P.R.M. Extracellular vesicles from human plasma and serum are carriers of extravesicular cargo-Implications for biomarker discovery. PLoS One. 2020;15(8):e0236439. https://doi.org/10.1371/journal.pone.0236439

35. Wade S.M., Trenkmann M., McGarry T., Canavan M., Marzaioli V., Wade S.C., Veale D.J., Fearon U. Altered expression of microRNA- 23a in psoriatic arthritis modulates synovial fibroblast pro-inflammatory mechanisms via phosphodiesterase 4B. J. Autoimmun. 2019;96:86-93 https://doi.org/10.1016/j.jaut.2018.08.008

36. Ciancio G., Ferracin M., Saccenti E., Bagnari V., Farina I., Furini F., Galuppi E., Zagatti B., Trotta F., Negrini M., Govoni M. Characterisation of peripheral blood mononuclear cell microRNA in early onset psoriatic arthritis. Clin. Exp. Rheumatol. 2017;35(1):113-121.

37. Villanova F., Di Meglio P., Nestle F.O. Biomarkers in psoriasis and psoriatic arthritis. Ann. Rheum. Dis. 2013;72 Suppl 2:ii104-10. https://doi.org/10.1136/annrheumdis-2012-203037

38. Balzano F., Deiana M., Dei Giudici S., Oggiano A., Baralla A., Pasella S., Mannu A., Pescatori M., Porcu B., Fanciulli G., Zinellu A., Carru C., Deiana L. miRNA Stability in Frozen Plasma Samples. Molecules. 2015;20(10):19030-19040. https://doi.org/10.3390/molecules201019030

39. Cheleschi S., Tenti S., Bedogni G., Fioravanti A. Circulating Mir-140 and leptin improve the accuracy of the differential diagnosis between psoriatic arthritis and rheumatoid arthritis: a case-control study. Transl. Res. 2022;239:18-34. https://doi.org/10.1016/j.trsl.2021.08.001

40. Bonek K., Kuca Warnawin E., Kornatka A., Plebańczyk M., Burakowski T., Maśliński W., Wisłowska M., Głuszko P., Ciechomska M. Circulating miRNA Correlates with Lipid Profile and Disease Activity in Psoriatic Arthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis Patients. Biomedicines. 2022;10(4):893. https://doi.org/10.3390/biomedicines10040893

41. Mease P.J., Antoni C.E., Gladman D.D., Taylor W.J. Psoriatic arthritis assessment tools in clinical trials. Ann. Rheum. Dis. 2005;64 Suppl 2(Suppl 2):ii49-54. https://doi.org/10.1136/ard.2004.034165

42. Pelosi A., Lunardi C., Fiore P.F., Tinazzi E., Patuzzo G., Argentino G., Moretta F., Puccetti A., Dolcino M. MicroRNA Expression Profiling in Psoriatic Arthritis. Biomed. Res. Int. 2018;2018:7305380. https://doi.org/10.1155/2018/7305380

43. Tillett W., Costa L., Jadon D., Wallis D., Cavill C., McHugh J., Korendowych E., McHugh N. The ClASsification for Psoriatic ARthritis (CASPAR) criteria--a retrospective feasibility, sensitivity, and specificity study. J. Rheumatol. 2012;39(1):154-156. https://doi.org/10.3899/jrheum.110845

44. Su Y.J. Early diagnosis of psoriatic arthritis among psoriasis patients: clinical experience sharing. Clin. Rheumatol. 2020;39(12):3677-3684. https://doi.org/10.1007/s10067-020-05132-1

45. Lin S.H., Ho J.C., Li S.C., Cheng Y.W., Yang Y.C., Chen J.F., Hsu C.Y., Nakano T., Wang F.S., Yang M.Y., Lee C.H., Hsiao C.C. Upregulation of miR-941 in Circulating CD14+ Monocytes Enhances Osteoclast Activation via WNT16 Inhibition in Patients with Psoriatic Arthritis. Int. J. Mol. Sci. 2020;21(12):4301. https://doi.org/10.3390/ijms21124301

46. Hu G., Zhang N., Li J., Wang J., Wu W., Li J., Tong W., Zhao X., Dai L., Zhang X. Tumor Necrosis Factor Receptor Associated Factor 3 Modulates Cartilage Degradation through Suppression of Interleukin 17 Signaling. Am. J. Pathol. 2020;190(8):1701-1712. https://doi.org/10.1016/j.ajpath.2020.04.016

47. Liu Z., Chen S., Yang Y., Lu S., Zhao X., Hu B., Pei H. MicroRNA-671-3p regulates the development of knee osteoarthritis by targeting TRAF3 in chondrocytes. Mol. Med. Rep. 2019;20(3):2843-2850. https://doi.org/10.3892/mmr.2019.10488

48. Costa V., De Fine M., Carina V., Conigliaro A., Raimondi L., De Luca A., Bellavia D., Salamanna F., Alessandro R., Pignatti G., Fini M., Giavaresi G. How miR-31-5p and miR-33a-5p Regulates SP1/CX43 Expression in Osteoarthritis Disease: Preliminary Insights. Int. J. Mol. Sci. 2021;22(5):2471. https://doi.org/10.3390/ijms22052471

49. Huang Z., Xing S., Liu M., Deng W., Wang Y., Huang Z., Huang Y., Huang X., Wu C., Guo X., Pan X., Jiang J., Feng F., Li T. MiR-26a- 5p enhances cells proliferation, invasion, and apoptosis resistance of fibroblast-like synoviocytes in rheumatoid arthritis by regulating PTEN/ PI3K/AKT pathway. Biosci. Rep. 2019;39(7):BSR20182192. https://doi.org/10.1042/BSR20182192

50. Guo T., Ding H., Jiang H., Bao N., Zhou L., Zhao J. miR-338-5p Regulates the Viability, Proliferation, Apoptosis and Migration of Rheumatoid Arthritis Fibroblast-Like Synoviocytes by Targeting NFAT5. Cell. Physiol. Biochem. 2018;49(3):899-910. https://doi.org/10.1159/000493222

51. Hussain N., Zhu W., Jiang C., Xu J., Geng M., Wu X., Hussain S., Wang B., Rajoka M.S.R., Li Y., Tian J., Meng L., Lu S. Down-regulation of miR-10a-5p promotes proliferation and restricts apoptosis via targeting T-box transcription factor 5 in inflamed synoviocytes. Biosci. Rep. 2018;38(2):BSR20180003. https://doi.org/10.1042/BSR20180003

52. Song A.F., Kang L., Wang Y.F., Wang M. MiR-34a-5p inhibits fibroblastlike synoviocytes proliferation via XBP1. Eur. Rev. Med. Pharmacol. Sci. 2020;24:11675-11682. https://doi.org/10.26355/eurrev_202011_23812

53. Li H.Z., Xu X.H., Lin N., Wang D.W., Lin Y.M., Su Z.Z., Lu H.D. Overexpression of miR-10a-5p facilitates the progression of osteoarthritis. Aging (Albany NY). 2020;12(7):5948-5976. https://doi.org/10.18632/aging.102989

54. Endisha H., Datta P., Sharma A., Nakamura S., Rossomacha E., Younan C., Ali S.A., Tavallaee G., Lively S., Potla P., Shestopaloff K., Rockel J.S., Krawetz R., Mahomed N.N., Jurisica I., Gandhi R., Kapoor M. MicroRNA-34a-5p Promotes Joint Destruction During Osteoarthritis. Arthritis Rheumatol. 2021;73(3):426-439. https://doi.org/10.1002/art.41552

55. Motta F., Pederzani A., Carena M.C., Ceribelli A., Wordsworth P.B., De Santis M., Selmi C., Vecellio M. MicroRNAs in Axial Spondylarthritis: an Overview of the Recent Progresses in the Field with a Focus on Ankylosing Spondylitis and Psoriatic Arthritis. Curr. Rheumatol. Rep. 2021;23(8):59. https://doi.org/10.1007/s11926-021-01027-5

56. Ciancio G., Ferracin M., Saccenti E., Bagnari V., Farina I., Furini F., Galuppi E., Zagatti B., Trotta F., Negrini M., Govoni M. Characterisationof peripheral blood mononuclear cell microRNA in early onset psoriatic arthritis. Clin. Exp. Rheumatol. 2017;35(1):113-121.

57. FitzGerald O., Behrens F., Barton A., Bertheussen H., BoutouyrieDumont B., Coates L., Davies O., de Wit M., Fagni F., Goodyear C.S., Gurke R., Hahnefeld L., Huppertz C., Ioannidis V., Ibberson M., Katz A., Klippstein M., Koehm M., Korish S., Mackay S., Martin D.A., O’Sullivan D., Patel K., Rueping S., Schett G., Scholich K., Schwenk J.M., Siebert S., Simon D., Vivekanantham A., Pennington S.R. Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis. Ther. Adv. Musculoskelet. Dis. 2023;15:1759720X231192315. https://doi.org/10.1177/1759720X231192315

58. Moldovan L., Batte K.E., Trgovcich J., Wisler J., Marsh C.B., Piper M. Methodological challenges in utilizing miRNAs as circulating biomarkers. J. Cell. Mol. Med. 2014;18(3):371-90. https://doi.org/10.1111/jcmm.12236

59. Singh R, Ramasubramanian B, Kanji S, Chakraborty AR, Haque SJ, Chakravarti A. Circulating microRNAs in cancer: Hope or hype? Cancer Lett. 2016 Oct 10;381(1):113-21. https://doi.org/10.1016/j.canlet.2016.07.002